A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
Clinical trial NCT01609231 · TERMINATED
Trial details
- NCT number
- NCT01609231
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-06
- Primary completion
- 2014-12-09
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.